search
Back to results

Time-Restricted Feeding on Glucose Homeostasis and Quality of Life

Primary Purpose

Diabetes Mellitus, Type 2, Time Restricted Feeding

Status
Unknown status
Phase
Not Applicable
Locations
Kuwait
Study Type
Interventional
Intervention
TRF
Normal timing of food intake
Sponsored by
Dasman Diabetes Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must agree to follow time restricted feeding protocol if randomized to the TRF arm.
  • Age 21-65 years
  • T2DM with any diabetes medication
  • BMI of 25-45 kg/m2
  • Wake up at a regular time between 5-8 am
  • Able to provide informed consent.

Exclusion Criteria:

  • Weight loss of more than 5 kg within the past 6 months
  • HbA1c of <6·5% and >12%
  • Serious current or recent illness including cancer or severe or unstable heart failure.
  • Participation in another clinical research trial.
  • Current treatment with anti-obesity drugs.
  • Substance abuse
  • Learning difficulties
  • Presence of an eating disorder
  • Purging behaviour
  • Pregnancy or consideration of pregnancy
  • Hospital admission for depression or use of antipsychotic drugs.
  • Regularly eat within a <9-hour period each day
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Sites / Locations

  • Dasman Diabetes InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

TRF

Normal timing of food intake.

Arm Description

Eating restricted to between midday and 6pm.

Eating between 8am and 11pm.

Outcomes

Primary Outcome Measures

HbA1c
Change in HbA1c between the intervention and control arms.

Secondary Outcome Measures

Body weight
Change in body weight between the intervention and control arms.
Insulin sensitivity
Change insulin sensitivitiy assessed by OGTT between the intervention and control arms.
Diabetes medications
Change in diabetes medications between the intervention and control arms.
Inflammatory markers
Change in TNF-alpha in pg/mL between the intervention and control arms.
Inflammatory markers
Change in IL-10 in pg/mL between the intervention and control arms.
Inflammatory markers
Change in IL-6 in pg/mL between the intervention and control arms.
Inflammatory markers
Change in IL-18 in pg/mL between the intervention and control arms.
Inflammatory markers
Change in CRP in mg/L between the intervention and control arms.
Inflammatory markers
Change in adiponectin in µg/mL the intervention and control arms.

Full Information

First Posted
August 18, 2019
Last Updated
December 11, 2019
Sponsor
Dasman Diabetes Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04062773
Brief Title
Time-Restricted Feeding on Glucose Homeostasis and Quality of Life
Official Title
A Pilot Study to Evaluate the Effect of Time-Restricted Feeding on Blood Glucose, Insulin Sensitivity and Quality of Life
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 10, 2019 (Actual)
Primary Completion Date
March 1, 2020 (Anticipated)
Study Completion Date
March 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dasman Diabetes Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Time-restricted feeding can improve insulin sensitivity, and increase fat oxidation in people with prediabetes independent of weight loss. It may also help people to lose weight. However, it has not been tested in people with type 2 diabetes. Plan of investigation: Participants meeting the eligibility criteria will be randomized to the TRF arm or the continuous eating arm. Both arms with be given a prescribed dietary plan to help them lose 5% of body weight. In the TRF they will permitted to eat between midday and 6pm. In the continuous eating arm they will be allowed to eat between 8am and 11pm. Participants will attend the nutrition clinic every two weeks to be weighed and be given personalized support to help them follow their assigned diet. Prior to starting the diets outcome measures will be taken: Glycaemia will be measured by a glucose tolerance test, and 7-day continuous glucose monitoring. HbA1c will be taken from fasting blood sample. In addition, the fasting sample will be taken for measurement of insulin, lipid profile and inflammatory markers. We will also use questionnaires to assess quality of life, a 3-day food diary to assess compliance to diet especially meal timings. Capillary ketones will also be used to assess whether compliance to the assigned fasting period. Outcome measures will also be taken during 7 days of the second month, and then the final seven days of the last month on the diet. The primary outcome is HbA1c.
Detailed Description
Experimental Design 12-week parallel randomised control trial Recruitment We will recruit via advertisements outside Dasman using social media and local ads in addition to screening of Dasman Registry for any potential participants. Opportunistic recruitment will also occur by DDI dietitians. Following telephone screening to ensure the potential participant meets initial screening criteria we will carry out a medical screening to ensure the person can take part. Environment All screening, dietary counselling visits, and placement of the CGM will take place at the Dasman Diabetes Institute (DDI). The institute has extensive space for interventional studies, including screening rooms, body composition assessment and clinical rooms for placement of the CGM monitor. STUDY INTERVENTIONS For both groups all participants will be guided towards a 5% weight loss based on individualised energy requirements. The difference will be the hours during which the participants consume their required calories. Time restricted feeding group: Will consume their calories between 12pm and 6pm. Continuous energy restriction group: Will consume their calories between 8am and 11pm. Participants will be guided towards their weight loss during one-to-one visits at baseline and every 2 weeks for 12 weeks. Procedures At baseline and follow-up all participants will undergo an oral glucose tolerance test. A blood sample will also be taken for HbA1c, lipid profile, fasting insulin, inflammatory factors and a sample for Biobank. The biobank sample will be stored to enable us, with other researchers at DDI to understand the heterogeneity of type 2 diabetes; whether certain people respond to dietary interventions based on their genetic, epigenetic or metabolomic background; and ultimately will help guide clinical care. Participants will wear Flash Glucose monitoring or other continuous glucose monitoring device to measure their 24-hour blood glucose concentrations during the seven days preceding the start of the dietary intervention, seven days of the second month, and the final seven days of the third month. Participants will also measure their capillary ketones during the first three days of the first month, three days of the second month, and final three days of the third month. Medication changes: prandial medications (insulin or sulphonylurea) will be altered to the timing of meal intake. Any reduction in medication due to changes in glucose will be carried out by the patient's doctor. A quality of life questionnaire: PAID. A 3 day food diary with meal times to check compliance. Statistical Methods This is a pilot study. We will recruit 25 people per group. This is based on recommendations for sample sizes for feasibility and pilot studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Time Restricted Feeding

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
12 week parallel trial.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TRF
Arm Type
Experimental
Arm Description
Eating restricted to between midday and 6pm.
Arm Title
Normal timing of food intake.
Arm Type
Placebo Comparator
Arm Description
Eating between 8am and 11pm.
Intervention Type
Behavioral
Intervention Name(s)
TRF
Intervention Description
time restricted feeding group
Intervention Type
Behavioral
Intervention Name(s)
Normal timing of food intake
Intervention Description
no time restricted feeding
Primary Outcome Measure Information:
Title
HbA1c
Description
Change in HbA1c between the intervention and control arms.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Body weight
Description
Change in body weight between the intervention and control arms.
Time Frame
12 weeks
Title
Insulin sensitivity
Description
Change insulin sensitivitiy assessed by OGTT between the intervention and control arms.
Time Frame
12 weeks
Title
Diabetes medications
Description
Change in diabetes medications between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in TNF-alpha in pg/mL between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in IL-10 in pg/mL between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in IL-6 in pg/mL between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in IL-18 in pg/mL between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in CRP in mg/L between the intervention and control arms.
Time Frame
12 weeks
Title
Inflammatory markers
Description
Change in adiponectin in µg/mL the intervention and control arms.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must agree to follow time restricted feeding protocol if randomized to the TRF arm. Age 21-65 years T2DM with any diabetes medication BMI of 25-45 kg/m2 Wake up at a regular time between 5-8 am Able to provide informed consent. Exclusion Criteria: Weight loss of more than 5 kg within the past 6 months HbA1c of <6·5% and >12% Serious current or recent illness including cancer or severe or unstable heart failure. Participation in another clinical research trial. Current treatment with anti-obesity drugs. Substance abuse Learning difficulties Presence of an eating disorder Purging behaviour Pregnancy or consideration of pregnancy Hospital admission for depression or use of antipsychotic drugs. Regularly eat within a <9-hour period each day Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicola Guess, PhD
Phone
+965 2224 2999
Ext
2033
Email
Nicola.Guess@dasmaninstitute.org
Facility Information:
Facility Name
Dasman Diabetes Institute
City
Kuwait City
ZIP/Postal Code
15462
Country
Kuwait
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Guess, PhD
Phone
+965 2224 2999
Ext
2033
Email
Nicola.Guess@dasmaninstitute.org

12. IPD Sharing Statement

Learn more about this trial

Time-Restricted Feeding on Glucose Homeostasis and Quality of Life

We'll reach out to this number within 24 hrs